TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 173 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2021. The put-call ratio across all filers is 4.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $71,782,000 | -32.5% | 953,914 | -75.9% | 0.01% | -18.2% |
| Q1 2022 | $106,397,000 | -41.5% | 3,962,652 | +4.0% | 0.01% | -31.2% |
| Q4 2021 | $181,812,000 | -16.7% | 3,811,568 | +16.0% | 0.02% | -23.8% |
| Q3 2021 | $218,281,000 | -3.3% | 3,285,881 | +13.5% | 0.02% | 0.0% |
| Q2 2021 | $225,797,000 | -5.3% | 2,894,095 | +14.8% | 0.02% | -12.5% |
| Q1 2021 | $238,465,000 | -23.1% | 2,521,043 | -1.0% | 0.02% | -25.0% |
| Q4 2020 | $310,204,000 | +81.9% | 2,545,785 | +30.4% | 0.03% | +60.0% |
| Q3 2020 | $170,502,000 | +38.4% | 1,951,718 | +2.3% | 0.02% | +33.3% |
| Q2 2020 | $123,188,000 | +105.5% | 1,907,229 | +42.1% | 0.02% | +66.7% |
| Q1 2020 | $59,958,000 | -35.6% | 1,342,539 | -10.2% | 0.01% | -25.0% |
| Q4 2019 | $93,150,000 | +103.9% | 1,495,426 | +23.1% | 0.01% | +100.0% |
| Q3 2019 | $45,679,000 | +26.1% | 1,214,857 | +36.5% | 0.01% | +20.0% |
| Q2 2019 | $36,225,000 | – | 890,050 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |